Earnings Call Intelligence Subscribe
Home › Call Sheets › MRK › Q4'25
Call sheet · Q4'25

Merck (MRK)

Q4'25 earnings call · held February 3, 2026 · compared with the Q3'25 call · management-credibility review
9/12
Disclosure score
4 medium, 1 low flags
Financial quality
Bottom line
The sleeper story is MK1406 - a potential $5B+ influenza prevention blockbuster that's flying under the radar while everyone focuses on post-KEYTRUDA growth math. Yes, the $70B pipeline valuation sounds impressive, but 2026 guidance of just 1-3% growth reveals the harsh reality of near-term headwinds. The binding constraint isn't science - it's time. They need these assets to launch and ramp faster than historical precedent suggests is possible. Rob's most telling quote: 'We have line of sight to over $70 billion... more than double consensus 2028 peak KEYTRUDA revenue' - the math works, but the timeline is tight. My view changes if MK1406 shows compelling interim data in 2026 or if they accelerate QLEX conversion beyond the 30-40% target.

The 30-second version

  • SLEEPER STORY: MK1406 influenza prevention asset quietly becomes a $5B+ opportunity
  • KEYTRUDA patent runway potentially extends to Nov 2029, but management still planning for 2028
  • Post-LOE growth story gets real: $70B pipeline opportunity, but 2026 revenue growth anemic at 1-3%

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$17.3B (+4%)$16.4B (+5%)Decelerated to +5% from strong Q3
KEYTRUDA Sales$8.1B (+8%)$8.4B (+5%)Growth slowing, timing impact of -$200M
Non-GAAP EPS$2.58$2.04Down 21% QoQ, missed expectations
WINREVAIR Sales$360M$467M+30% QoQ, >27K total Rx dispensed
GARDASIL Sales$1.7B (-25%)$1.0B (-35%)Decline accelerated, China/Japan weakness
Operating Expenses$6.6B$6.8BUp 3% QoQ, BD charges $150M vs $300M prior
Gross Margin81.9%79.7%Declined 220 bps, inventory reserves hit
Animal Health Sales+7%+6%Slight deceleration but still solid
WELIREG Sales$196M (+41%)$220M (+37%)Growth rate slowing from high base
CAPVAXIVE Sales$244M$279M+14% QoQ, pneumococcal uptake strong

Accountability tracked

8 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRK Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.